The present study aimed to formulate and characterize an intranasal mucoadhesive gel of loratadine to enhance its bioavailability. Loratadine, an antihistamine, is commonly used for the treatment of allergic conditions, but its low bioavailability due to extensive first-pass metabolism can limit its effectiveness. To address this issue, an in situ gel formulation was developed using Poloxamer 407 and Carbopol 934 as excipients. The gel's physicochemical properties, including pH, drug content, viscosity, gel strength, gelation temperature, and drug release profile, were evaluated. FT-IR analysis revealed no significant chemical interaction between the drug and excipients, confirming the stability of the formulation. The gel exhibited shear-thinning behavior and gelation temperatures suitable for nasal administration. In vitro drug release studies showed a sustained release profile, with higher Carbopol concentrations resulting in slower drug release. The mucoadhesion time increased with Carbopol 934 concentration, ensuring prolonged retention at the nasal site. Stability studies demonstrated that the formulations remained stable under standard storage conditions. The results suggest that the loratadine-loaded mucoadhesive gel has the potential to improve the bioavailability of loratadine through intranasal delivery, offering a promising alternative to conventional oral dosage forms. Keywords: Loratadine, Mucoadhesive Gel, Poloxamer 407, Carbopol 934, In Situ Gel, Bioavailability, Drug Release, Nasal Delivery, Stability, FT-IR
Read full abstract